June 26 2025, David R Brown
IMCD acquires Trichem to accelerate its growth in the pharmaceutical markets in India
IMCD N.V., a global leading partner for the distribution and formulation of speciality chemicals and ingredients, has announced the acquisition of 100% of the shares in Trichem Healthcare Private Limited, Trichem Lifesciences Limited and Chemistry & Health FZ LLC.
With India being a major supplier of the world's generic drugs, this acquisition further enhances our portfolio, in particular with active pharmaceutical ingredients
Narendra Varde
Managing Director of IMCD India
Founded in 1998 and headquartered in Mumbai, India, Trichem has built a strong reputation in the healthcare sector, supplying high-quality active pharmaceutical ingredients, pharmaceutical intermediates, and formulation solutions. The company also provides regulatory assistance for customers serving the highly regulated pharmaceutical markets in India.
With 36 employees, Trichem operates across India and the Middle East, generating annual revenue of approximately INR 1.7 billion (ca. EUR 18 million) for the financial year ended 31 March 2025. About 33% of this revenue comes from commission income.
“With India being a major supplier of the world's generic drugs, this acquisition further enhances our portfolio, in particular with active pharmaceutical ingredients, and reinforces our position in the region's life-sciences industry,” said Narendra Varde, Managing Director of IMCD India. “Additionally, we are excited to welcome Trichem's talented team, whose deep market expertise and strong industry relationships will be invaluable to IMCD.”
Chetan Jain, Founder and Promoter of Trichem Group, added: “IMCD and Trichem share a common vision, strong entrepreneurial spirit, and commitment to building lasting partnerships. I am extremely proud of Trichem's achievements over the past 27 years. Going forward with IMCD's global presence, and our strong global principal partnerships, I am confident that this business will deliver immense value to our stakeholders.”
About IMCD N.V.
IMCD is a market-leader in the sales, marketing, and distribution of speciality chemicals and ingredients. Its result-driven professionals provide market-focused solutions to suppliers and customers across EMEA, Americas and Asia-Pacific, offering a range of comprehensive product portfolios, including innovative formulations that embrace industry trends. IMCD's dedicated team of technical and commercial experts work in close partnership to tailor best-in-class solutions and provide value through expertise for around 60,000 plus customers and a diverse range of world class suppliers.
In 2024, with over 5,100 employees, IMCD realised revenues of EUR 4,728 million. IMCD N.V.'s shares are traded at Euronext Amsterdam (symbol: IMCD) and included in the Dutch ESG AEX index, as one of 25 companies within the AEX and AMX indices demonstrating best ESG practices.
Source(s): IMCD Press Release
Further Information
Visit: https://www.imcdgroup.com